Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | ATP4A | P20648 | 1/20 | 0.36 |
| ▸ | ATP4B | P51164 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607091 | 0.84 | CYP1A2 (0.48) | RHEBSMN1; SMN2KMT2APDCD1CD274 | |
| SCHEMBL3616401 | 0.84 | SMN1; SMN2 (0.46) | RHEBSMN1; SMN2ALDH1A1KMT2APTGER1 | |
| SCHEMBL3616398 | 0.84 | SMN1; SMN2 (0.46) | RHEBSMN1; SMN2ALDH1A1KMT2APTGER1 | |
| SCHEMBL3597738 | 0.80 | ALDH1A1 (0.40) | RHEBSMN1; SMN2ALDH1A1KMT2APTGDR2 | |
| SCHEMBL3604504 | 0.76 | RHEB (0.41) | RHEBSMN1; SMN2ATP4AATP4BMAPK14 | |
| SCHEMBL3608988 | 0.74 | CYP1A2 (0.50) | RHEBSMN1; SMN2KMT2APDCD1CD274 | |
| SCHEMBL3610486 | 0.73 | PTGDR2 (0.49) | SMN1; SMN2ALDH1A1KMT2APTGDR2LMNA | |
| SCHEMBL3612387 | 0.73 | SLC22A12 (0.42) | ALDH1A1KMT2APTGDR2 | |
| SCHEMBL3608007 | 0.72 | KDM4E (0.39) | ALDH1A1KMT2APTGDR2 | |
| SCHEMBL3609981 | 0.72 | KDM4E (0.39) | ALDH1A1KMT2APTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128138-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | SLC5A1, SLC5A2, GLP1R | RHEB 2530/4885SMN1; SMN2 4515/4885ALDH1A1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.